Actinogen Medical Ltd (ASX: ACW) has announced a significant milestone in the development of its lead candidate, Xanamem®(emestedastat), with the 100th participant now enrolled in its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial. This event formally triggers the timeline for an independent interim analysis of safety and efficacy, bringing the company one step closer to potentially introducing a novel oral therapy for Alzheimer’s disease (AD).

Actinogen Medical Limited (ASX: ACW) is advancing one of the most promising neuroscience drug candidates in the global biotech pipeline. With its novel oral drug Xanamem® (emestedastat), the company is targeting two of the largest and most urgent unmet needs in modern medicine: Alzheimer’s disease (AD) and Major Depressive Disorder (MDD).